<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01246583</url>
  </required_header>
  <id_info>
    <org_study_id>A3921116</org_study_id>
    <nct_id>NCT01246583</nct_id>
  </id_info>
  <brief_title>CP-690-550 Ointment For Chronic Plaque Psoriasis</brief_title>
  <official_title>A PHASE 2A, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE PILOT EFFICACY, SAFETY, AND PHARMACOKINETICS OF 2 OINTMENT FORMULATIONS OF CP-690,550 IN SUBJECTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to see whether CP-690,550 ointment has potential as a safe and&#xD;
      effective treatment for adult patients with mild to moderate chronic plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2011</start_date>
  <completion_date type="Actual">November 29, 2011</completion_date>
  <primary_completion_date type="Actual">November 29, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Weeks 1, 2 and 3</measure>
    <time_frame>Baseline, Weeks 1, 2, 3</time_frame>
    <description>Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Target Plaque Severity Score (TPSS) of Erythema, Induration and Scaling at Weeks 1, 2, 3 and 4</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, 4</time_frame>
    <description>Target plaque severity was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment Area Overall Severity of Psoriasis Response of &quot;Clear&quot; (0) or &quot;Almost Clear&quot; (1)</measure>
    <time_frame>Week 1, 2, 3, 4</time_frame>
    <description>Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score range: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Decrease From Baseline of Greater Than or Equal to 2 Points in Treatment Area Overall Severity of Psoriasis Score</measure>
    <time_frame>Week 1, 2, 3, 4</time_frame>
    <description>Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Target Plaque Area at Week 1, 2, 3 and 4</measure>
    <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
    <description>A tracing of the target plaque on transparent film was used to quantify the target plaque area. The target plaque area was calculated by image analysis (planimetry). At baseline, target plaque area was determined prior to randomization to confirm the target plaque size of at least 9 cm^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch Severity Item (ISI)</measure>
    <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
    <description>The severity of itch was assessed using a single-item Patient Reported Outcome (PRO). Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Treatment Area Itch Severity Item (ISI) at Week 1, 2, 3 and 4</measure>
    <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
    <description>The severity of itch was assessed using a single-item PRO. Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Response Category</measure>
    <time_frame>Week 4</time_frame>
    <description>The PSSM evaluates overall participants satisfaction with the study treatment. Participants response evaluation was based on single 7-point item: 1=very satisfied, 2=somewhat satisfied, 3=slightly satisfied, 4=neither satisfied nor dissatisfied, 5=slightly dissatisfied, 6=somewhat dissatisfied, and 7=very dissatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Administration Site Adverse Events</measure>
    <time_frame>Baseline up to follow up visit (Day 36-39 after last dose of study treatment) (up to maximum of 9.5 weeks)</time_frame>
    <description>An adverse event was any untoward medical occurrence attributed to study drug in a participant who received study drug. Application site adverse event included documentation of any clinically significant local reaction, e.g erosion, vesicles or scabbing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Burning/Stinging of Psoriatic or Perilesional Skin in The Treatment Area</measure>
    <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
    <description>Burning/stinging symptoms at the treatment area including target plaque, additional plaque/s within the treatment area (if any) and treated perilesional skin (if any) were queried from the participants and scored by the investigator using a 4-point scale: 0=none; 1=Mild; 2=Moderate; 3=Severe. Except at baseline pre-dosing, burning/stinging was assessed for 2 time periods based on the maximum burning or stinging that the participant has experienced: Immediate (within 5 minutes after application); Persistent (beyond 5 minutes after application).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Draize Score of Perilesional Skin in The Treatment Area</measure>
    <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
    <description>Draize scoring evaluated perilesional skin within treatment area for erythema and presence/absence of other signs and symptoms. Erythema score ranged from 0 to 4 as: 0(no reaction visible), 1(trace reactions- barely perceptible pinkness), 2(mild reaction- readily visible pinkness), 3(moderate reaction- definite redness), 4 (Strong to severe reaction- very intense redness). Letter grade defined as: J(Burning, stinging, itching), E(Edema), P(Papules), V(Vesicles), B(Bulla reaction), S(Spreading), W(Weeping), I(Induration), XC(Additional comments). Superficial observations defined as: G(Glazing), Y(Peeling), C(Scab), D(Hyperpigmentation), H(Hypopigmentation), F(Fissuring), R(Erosion), U(Ulceration), K(Scaling). Erythema and other signs/symptoms with at least 1 participant with Draize Score of Perilesional Skin in the treatment area were reported in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic and Diastolic Blood Pressure at Week 1, 2, 3, 4</measure>
    <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
    <description>Blood pressure (BP) was measured in duplicate (approximately 5 minutes apart) using a standard calibrated BP measuring device. BP defined as pressure exerted by circulating blood upon walls of blood vessels. Diastolic BP is minimum pressure in arteries, near beginning of cardiac cycle when ventricles are filled with blood. Systolic BP is peak pressure in arteries, near end of the cardiac cycle when ventricles are contracting. Normal blood pressure is less than 120 millimeters of mercury (mmHg) systolic and less than 80 mmHg diastolic. Change=value at week 1, 2, 3, 4 minus value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate at Week 1, 2, 3, 4</measure>
    <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
    <description>Heart (pulse) rate was measured in duplicate (approximately 5 minutes apart) for a minimum of 30 seconds. Heart rate is the number of heartbeats per unit of time, usually per minute. The heart rate is based on the number of contractions of the ventricles (the lower chambers of the heart). Change=value at week 1, 2, 3, 4 minus value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Electrocardiogram (ECG) Findings at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>A single standard supine 12-lead Electrocardiogram (ECG) was performed after the participant had rested quietly for at least 10 minutes. ECG parameters included RR interval, PR interval, QRS complex, QT interval, QTcB (corrected for heart rate using Bazett's formula) interval, and QTcF (corrected for heart rate using Fridericia's formula) interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin Level at Week 2, 4</measure>
    <time_frame>Baseline, Week 2, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelet and Neutrophil Count at Week 2, 4</measure>
    <time_frame>Baseline, Week 2, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Creatinine Level at Week 2, 4</measure>
    <time_frame>Baseline, Week 2, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Creatine Kinase (CK) Level at Week 2, 4</measure>
    <time_frame>Baseline, Week 2, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of CP-690,550</measure>
    <time_frame>0 (predose), 1, 2 and 4-9 hours postdose on Day 29 or early termination</time_frame>
    <description>Summary statistics were calculated by setting concentration values below the lower limit of quantification (lower limit of quantification=0.1 nanogram per milliliter [ng/mL]) to zero. Summary statistics were not presented if number of observations above lower limit of quantification (NALQ) = 0.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550 Ointment 1</intervention_name>
    <description>2% CP-690,550 Ointment 1 twice daily for 4 weeks</description>
    <arm_group_label>Treatment Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle 1</intervention_name>
    <description>Vehicle 1 twice daily for 4 weeks</description>
    <arm_group_label>Treatment Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550 Ointment 2</intervention_name>
    <description>2% CP-690,550 Ointment 2 twice daily for 4 weeks</description>
    <arm_group_label>Treatment Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle 2</intervention_name>
    <description>Vehicle 2 twice daily for 4 weeks</description>
    <arm_group_label>Treatment Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mild to moderate chronic plaque psoriasis (psoriasis vulgaris), with the duration of&#xD;
             at least 6 months;&#xD;
&#xD;
          -  A target plaque of at least 9 sq. cm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Demonstrates &quot;rebound&quot; or &quot;flare&quot; of chronic plaque psoriasis;&#xD;
&#xD;
          -  Non plaque form of psoriasis;&#xD;
&#xD;
          -  Currently have or history of psoriatic arthritis;&#xD;
&#xD;
          -  Current drug induced psoriasis;&#xD;
&#xD;
          -  Currently on systemic therapy or was on systemic therapy for psoriasis within the&#xD;
             previous 6 months;&#xD;
&#xD;
          -  Currently on phototherapy for psoriasis or was on phototherapy within the previous 3&#xD;
             months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Horizon Research Group, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Expresscare Medical</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Avenue Dermatology, PA</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modern Research Associates, PLLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K.Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siena Medical Research</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermatologique du Quebec metropolitain</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921116&amp;StudyName=CP-690-550%20Ointment%20For%20Chronic%20Plaque%20Psoriasis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <results_first_submitted>December 14, 2020</results_first_submitted>
  <results_first_submitted_qc>December 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2021</results_first_posted>
  <disposition_first_submitted>April 9, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 9, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 16, 2013</disposition_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multi Site</keyword>
  <keyword>Randomized</keyword>
  <keyword>Placebo Controlled</keyword>
  <keyword>Double Blind</keyword>
  <keyword>Parallel Group</keyword>
  <keyword>chronic plaque psoriasis</keyword>
  <keyword>topical treatment</keyword>
  <keyword>skin diseases</keyword>
  <keyword>papulosquamous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2% CP-690,550 Ointment 1</title>
          <description>CP-690,550 2 percent (%) ointment 1, containing a dermal penetration agent, was applied topically to a 300 square centimeter (cm^2) treatment area twice daily at an application coverage of 3 milligram per cm^2 (mg/cm^2) for 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Vehicle 1</title>
          <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>2% CP-690,550 Ointment 2</title>
          <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Vehicle 2</title>
          <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2% CP-690,550 Ointment 1</title>
          <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Vehicle 1</title>
          <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>2% CP-690,550 Ointment 2</title>
          <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Vehicle 2</title>
          <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>18 to 44 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>45 to 64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Greater than or equal to 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4</title>
        <description>Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Full analysis set (FAS) included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here Overall Number of Participants Analyzed signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4</title>
          <description>Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.</description>
          <population>Full analysis set (FAS) included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here Overall Number of Participants Analyzed signifies those participants who were evaluable for this measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.97" spread="29.93"/>
                    <measurement group_id="O2" value="-41.01" spread="20.29"/>
                    <measurement group_id="O3" value="-24.26" spread="33.43"/>
                    <measurement group_id="O4" value="-17.24" spread="25.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Weeks 1, 2 and 3</title>
        <description>Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.</description>
        <time_frame>Baseline, Weeks 1, 2, 3</time_frame>
        <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here Overall Number of Participants Analyzed= participants who were evaluable for this measure. Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Weeks 1, 2 and 3</title>
          <description>Target plaque was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The individual signs severity sub scores were summed to calculate TPSS. The total score varied in increments of 1 and ranged from 1 to 12, with higher scores representing greater severity of psoriasis.</description>
          <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here Overall Number of Participants Analyzed= participants who were evaluable for this measure. Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.00" spread="28.54"/>
                    <measurement group_id="O2" value="-25.59" spread="18.98"/>
                    <measurement group_id="O3" value="-12.65" spread="22.19"/>
                    <measurement group_id="O4" value="-6.39" spread="23.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.32" spread="29.46"/>
                    <measurement group_id="O2" value="-28.68" spread="20.72"/>
                    <measurement group_id="O3" value="-17.26" spread="27.50"/>
                    <measurement group_id="O4" value="-10.32" spread="26.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.90" spread="31.92"/>
                    <measurement group_id="O2" value="-33.12" spread="18.92"/>
                    <measurement group_id="O3" value="-26.32" spread="32.48"/>
                    <measurement group_id="O4" value="-27.92" spread="19.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Target Plaque Severity Score (TPSS) of Erythema, Induration and Scaling at Weeks 1, 2, 3 and 4</title>
        <description>Target plaque severity was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked.</description>
        <time_frame>Baseline, Weeks 1, 2, 3, 4</time_frame>
        <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Target Plaque Severity Score (TPSS) of Erythema, Induration and Scaling at Weeks 1, 2, 3 and 4</title>
          <description>Target plaque severity was evaluated individually for signs of induration, scaling and erythema. Each of the 3 signs was rated on 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked.</description>
          <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="0.59"/>
                    <measurement group_id="O2" value="2.62" spread="0.51"/>
                    <measurement group_id="O3" value="2.44" spread="0.51"/>
                    <measurement group_id="O4" value="2.50" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 1: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.77"/>
                    <measurement group_id="O2" value="-0.77" spread="0.73"/>
                    <measurement group_id="O3" value="-0.26" spread="0.62"/>
                    <measurement group_id="O4" value="-0.11" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="0.83"/>
                    <measurement group_id="O2" value="-0.83" spread="0.58"/>
                    <measurement group_id="O3" value="-0.42" spread="0.72"/>
                    <measurement group_id="O4" value="-0.14" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 3: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="0.90"/>
                    <measurement group_id="O2" value="-1.00" spread="0.58"/>
                    <measurement group_id="O3" value="-0.57" spread="0.87"/>
                    <measurement group_id="O4" value="-0.75" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="0.83"/>
                    <measurement group_id="O2" value="-1.15" spread="0.69"/>
                    <measurement group_id="O3" value="-0.61" spread="0.89"/>
                    <measurement group_id="O4" value="-0.44" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Induration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="0.67"/>
                    <measurement group_id="O2" value="2.46" spread="0.52"/>
                    <measurement group_id="O3" value="2.28" spread="0.46"/>
                    <measurement group_id="O4" value="2.40" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 1: Induration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.82"/>
                    <measurement group_id="O2" value="-0.38" spread="0.77"/>
                    <measurement group_id="O3" value="-0.17" spread="0.58"/>
                    <measurement group_id="O4" value="0.00" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: Induration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="0.80"/>
                    <measurement group_id="O2" value="-0.58" spread="0.79"/>
                    <measurement group_id="O3" value="-0.33" spread="0.70"/>
                    <measurement group_id="O4" value="-0.14" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 3: Induration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="0.73"/>
                    <measurement group_id="O2" value="-0.69" spread="0.63"/>
                    <measurement group_id="O3" value="-0.57" spread="0.81"/>
                    <measurement group_id="O4" value="-0.38" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: Induration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="0.70"/>
                    <measurement group_id="O2" value="-0.92" spread="0.64"/>
                    <measurement group_id="O3" value="-0.43" spread="0.90"/>
                    <measurement group_id="O4" value="-0.22" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Scaling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.65"/>
                    <measurement group_id="O2" value="2.23" spread="0.60"/>
                    <measurement group_id="O3" value="2.08" spread="0.49"/>
                    <measurement group_id="O4" value="2.30" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 1: Scaling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="0.85"/>
                    <measurement group_id="O2" value="-0.69" spread="0.48"/>
                    <measurement group_id="O3" value="-0.48" spread="0.95"/>
                    <measurement group_id="O4" value="-0.33" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: Scaling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="0.83"/>
                    <measurement group_id="O2" value="-0.75" spread="0.75"/>
                    <measurement group_id="O3" value="-0.38" spread="0.77"/>
                    <measurement group_id="O4" value="-0.43" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 3: Scaling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="0.88"/>
                    <measurement group_id="O2" value="-0.85" spread="0.99"/>
                    <measurement group_id="O3" value="-0.67" spread="1.02"/>
                    <measurement group_id="O4" value="-0.75" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: Scaling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="0.89"/>
                    <measurement group_id="O2" value="-1.00" spread="0.91"/>
                    <measurement group_id="O3" value="-0.61" spread="1.03"/>
                    <measurement group_id="O4" value="-0.56" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment Area Overall Severity of Psoriasis Response of &quot;Clear&quot; (0) or &quot;Almost Clear&quot; (1)</title>
        <description>Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score range: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.</description>
        <time_frame>Week 1, 2, 3, 4</time_frame>
        <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here, Overall Number of Participants Analyzed= participants who were evaluable for this measure. Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment Area Overall Severity of Psoriasis Response of &quot;Clear&quot; (0) or &quot;Almost Clear&quot; (1)</title>
          <description>Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score range: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.</description>
          <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here, Overall Number of Participants Analyzed= participants who were evaluable for this measure. Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.11"/>
                    <measurement group_id="O2" value="23.08"/>
                    <measurement group_id="O3" value="21.74"/>
                    <measurement group_id="O4" value="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.38"/>
                    <measurement group_id="O2" value="33.33"/>
                    <measurement group_id="O3" value="29.17"/>
                    <measurement group_id="O4" value="28.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.09"/>
                    <measurement group_id="O2" value="23.08"/>
                    <measurement group_id="O3" value="38.10"/>
                    <measurement group_id="O4" value="37.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.64"/>
                    <measurement group_id="O2" value="61.54"/>
                    <measurement group_id="O3" value="39.13"/>
                    <measurement group_id="O4" value="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Decrease From Baseline of Greater Than or Equal to 2 Points in Treatment Area Overall Severity of Psoriasis Score</title>
        <description>Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.</description>
        <time_frame>Week 1, 2, 3, 4</time_frame>
        <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here, Overall Number of Participants Analyzed= participants who were evaluable for this measure. Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Decrease From Baseline of Greater Than or Equal to 2 Points in Treatment Area Overall Severity of Psoriasis Score</title>
          <description>Treatment area overall severity of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the treatment area according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. Total possible score: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.</description>
          <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here, Overall Number of Participants Analyzed= participants who were evaluable for this measure. Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.79"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.57"/>
                    <measurement group_id="O2" value="8.33"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.82"/>
                    <measurement group_id="O2" value="15.38"/>
                    <measurement group_id="O3" value="9.52"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.36"/>
                    <measurement group_id="O2" value="23.08"/>
                    <measurement group_id="O3" value="17.39"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Target Plaque Area at Week 1, 2, 3 and 4</title>
        <description>A tracing of the target plaque on transparent film was used to quantify the target plaque area. The target plaque area was calculated by image analysis (planimetry). At baseline, target plaque area was determined prior to randomization to confirm the target plaque size of at least 9 cm^2.</description>
        <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
        <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here, Overall Number of Participants Analyzed= participants who were evaluable for this measure. Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Target Plaque Area at Week 1, 2, 3 and 4</title>
          <description>A tracing of the target plaque on transparent film was used to quantify the target plaque area. The target plaque area was calculated by image analysis (planimetry). At baseline, target plaque area was determined prior to randomization to confirm the target plaque size of at least 9 cm^2.</description>
          <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here, Overall Number of Participants Analyzed= participants who were evaluable for this measure. Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.26" spread="34.86"/>
                    <measurement group_id="O2" value="-11.26" spread="28.55"/>
                    <measurement group_id="O3" value="-3.72" spread="19.18"/>
                    <measurement group_id="O4" value="-3.50" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.67" spread="40.18"/>
                    <measurement group_id="O2" value="-8.35" spread="37.19"/>
                    <measurement group_id="O3" value="-5.52" spread="22.82"/>
                    <measurement group_id="O4" value="-18.72" spread="22.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.21" spread="42.22"/>
                    <measurement group_id="O2" value="-13.52" spread="42.92"/>
                    <measurement group_id="O3" value="-4.90" spread="30.23"/>
                    <measurement group_id="O4" value="-13.59" spread="38.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.39" spread="43.76"/>
                    <measurement group_id="O2" value="-19.61" spread="49.93"/>
                    <measurement group_id="O3" value="-8.71" spread="31.23"/>
                    <measurement group_id="O4" value="-4.98" spread="27.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Itch Severity Item (ISI)</title>
        <description>The severity of itch was assessed using a single-item Patient Reported Outcome (PRO). Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.</description>
        <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
        <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Itch Severity Item (ISI)</title>
          <description>The severity of itch was assessed using a single-item Patient Reported Outcome (PRO). Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.</description>
          <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="2.52"/>
                    <measurement group_id="O2" value="5.54" spread="3.10"/>
                    <measurement group_id="O3" value="4.36" spread="2.53"/>
                    <measurement group_id="O4" value="6.20" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" spread="2.54"/>
                    <measurement group_id="O2" value="4.69" spread="3.45"/>
                    <measurement group_id="O3" value="3.52" spread="2.74"/>
                    <measurement group_id="O4" value="4.22" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="2.23"/>
                    <measurement group_id="O2" value="3.92" spread="3.12"/>
                    <measurement group_id="O3" value="3.42" spread="2.57"/>
                    <measurement group_id="O4" value="4.71" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="2.42"/>
                    <measurement group_id="O2" value="3.69" spread="3.30"/>
                    <measurement group_id="O3" value="2.86" spread="2.59"/>
                    <measurement group_id="O4" value="3.50" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="2.04"/>
                    <measurement group_id="O2" value="3.38" spread="2.90"/>
                    <measurement group_id="O3" value="2.30" spread="2.20"/>
                    <measurement group_id="O4" value="4.44" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Treatment Area Itch Severity Item (ISI) at Week 1, 2, 3 and 4</title>
        <description>The severity of itch was assessed using a single-item PRO. Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.</description>
        <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
        <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here, Overall Number of Participants Analyzed=participants who were evaluable for this measure. Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Treatment Area Itch Severity Item (ISI) at Week 1, 2, 3 and 4</title>
          <description>The severity of itch was assessed using a single-item PRO. Participants were asked to assess their worst itching due to psoriasis at the treatment area over the past 24 hours on a numeric rating scale ranging from of 0-10 where, 0=no itching and 10=worst possible itching.</description>
          <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here, Overall Number of Participants Analyzed=participants who were evaluable for this measure. Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="2.04"/>
                    <measurement group_id="O2" value="-0.85" spread="1.63"/>
                    <measurement group_id="O3" value="-0.74" spread="2.22"/>
                    <measurement group_id="O4" value="-2.00" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.90" spread="2.14"/>
                    <measurement group_id="O2" value="-1.83" spread="3.24"/>
                    <measurement group_id="O3" value="-1.00" spread="2.38"/>
                    <measurement group_id="O4" value="-1.43" spread="3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="1.91"/>
                    <measurement group_id="O2" value="-1.85" spread="2.79"/>
                    <measurement group_id="O3" value="-1.62" spread="2.65"/>
                    <measurement group_id="O4" value="-2.75" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.64" spread="1.97"/>
                    <measurement group_id="O2" value="-2.15" spread="2.85"/>
                    <measurement group_id="O3" value="-2.13" spread="2.65"/>
                    <measurement group_id="O4" value="-1.78" spread="3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Response Category</title>
        <description>The PSSM evaluates overall participants satisfaction with the study treatment. Participants response evaluation was based on single 7-point item: 1=very satisfied, 2=somewhat satisfied, 3=slightly satisfied, 4=neither satisfied nor dissatisfied, 5=slightly dissatisfied, 6=somewhat dissatisfied, and 7=very dissatisfied.</description>
        <time_frame>Week 4</time_frame>
        <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here, Overall Number of Participants Analyzed signifies number of participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Response Category</title>
          <description>The PSSM evaluates overall participants satisfaction with the study treatment. Participants response evaluation was based on single 7-point item: 1=very satisfied, 2=somewhat satisfied, 3=slightly satisfied, 4=neither satisfied nor dissatisfied, 5=slightly dissatisfied, 6=somewhat dissatisfied, and 7=very dissatisfied.</description>
          <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Here, Overall Number of Participants Analyzed signifies number of participants who were evaluable for this measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="32.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="38.5"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="12.0"/>
                    <measurement group_id="O4" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither Satisfied nor Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                    <measurement group_id="O2" value="15.4"/>
                    <measurement group_id="O3" value="4.0"/>
                    <measurement group_id="O4" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4.0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="12.0"/>
                    <measurement group_id="O4" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="15.4"/>
                    <measurement group_id="O3" value="16.0"/>
                    <measurement group_id="O4" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Administration Site Adverse Events</title>
        <description>An adverse event was any untoward medical occurrence attributed to study drug in a participant who received study drug. Application site adverse event included documentation of any clinically significant local reaction, e.g erosion, vesicles or scabbing.</description>
        <time_frame>Baseline up to follow up visit (Day 36-39 after last dose of study treatment) (up to maximum of 9.5 weeks)</time_frame>
        <population>Safety analysis set included all participants who received at least one dose of the investigational drug (CP-690,550 or vehicle).</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Administration Site Adverse Events</title>
          <description>An adverse event was any untoward medical occurrence attributed to study drug in a participant who received study drug. Application site adverse event included documentation of any clinically significant local reaction, e.g erosion, vesicles or scabbing.</description>
          <population>Safety analysis set included all participants who received at least one dose of the investigational drug (CP-690,550 or vehicle).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Burning/Stinging of Psoriatic or Perilesional Skin in The Treatment Area</title>
        <description>Burning/stinging symptoms at the treatment area including target plaque, additional plaque/s within the treatment area (if any) and treated perilesional skin (if any) were queried from the participants and scored by the investigator using a 4-point scale: 0=none; 1=Mild; 2=Moderate; 3=Severe. Except at baseline pre-dosing, burning/stinging was assessed for 2 time periods based on the maximum burning or stinging that the participant has experienced: Immediate (within 5 minutes after application); Persistent (beyond 5 minutes after application).</description>
        <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
        <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle).</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Burning/Stinging of Psoriatic or Perilesional Skin in The Treatment Area</title>
          <description>Burning/stinging symptoms at the treatment area including target plaque, additional plaque/s within the treatment area (if any) and treated perilesional skin (if any) were queried from the participants and scored by the investigator using a 4-point scale: 0=none; 1=Mild; 2=Moderate; 3=Severe. Except at baseline pre-dosing, burning/stinging was assessed for 2 time periods based on the maximum burning or stinging that the participant has experienced: Immediate (within 5 minutes after application); Persistent (beyond 5 minutes after application).</description>
          <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: None, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mild, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Moderate, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Severe, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: None, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mild, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Moderate, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Severe, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: None, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: Mild, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: Moderate, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: Severe, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: None, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Mild, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Moderate, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Severe, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3: None, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3: Mild, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3: Moderate, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3: Severe, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: None, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Mild, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Moderate, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Severe, Immediate Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: None, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: Mild, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: Moderate, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: Severe, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: None, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Mild, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Moderate, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Severe, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3: None, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3: Mild, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3: Moderate, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3: Severe, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: None, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Mild, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Moderate, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Severe, Persistent Stinging/Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Draize Score of Perilesional Skin in The Treatment Area</title>
        <description>Draize scoring evaluated perilesional skin within treatment area for erythema and presence/absence of other signs and symptoms. Erythema score ranged from 0 to 4 as: 0(no reaction visible), 1(trace reactions- barely perceptible pinkness), 2(mild reaction- readily visible pinkness), 3(moderate reaction- definite redness), 4 (Strong to severe reaction- very intense redness). Letter grade defined as: J(Burning, stinging, itching), E(Edema), P(Papules), V(Vesicles), B(Bulla reaction), S(Spreading), W(Weeping), I(Induration), XC(Additional comments). Superficial observations defined as: G(Glazing), Y(Peeling), C(Scab), D(Hyperpigmentation), H(Hypopigmentation), F(Fissuring), R(Erosion), U(Ulceration), K(Scaling). Erythema and other signs/symptoms with at least 1 participant with Draize Score of Perilesional Skin in the treatment area were reported in this outcome measure.</description>
        <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
        <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle).</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Draize Score of Perilesional Skin in The Treatment Area</title>
          <description>Draize scoring evaluated perilesional skin within treatment area for erythema and presence/absence of other signs and symptoms. Erythema score ranged from 0 to 4 as: 0(no reaction visible), 1(trace reactions- barely perceptible pinkness), 2(mild reaction- readily visible pinkness), 3(moderate reaction- definite redness), 4 (Strong to severe reaction- very intense redness). Letter grade defined as: J(Burning, stinging, itching), E(Edema), P(Papules), V(Vesicles), B(Bulla reaction), S(Spreading), W(Weeping), I(Induration), XC(Additional comments). Superficial observations defined as: G(Glazing), Y(Peeling), C(Scab), D(Hyperpigmentation), H(Hypopigmentation), F(Fissuring), R(Erosion), U(Ulceration), K(Scaling). Erythema and other signs/symptoms with at least 1 participant with Draize Score of Perilesional Skin in the treatment area were reported in this outcome measure.</description>
          <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Erythema: Moderate Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Letter Grade: Burning, Stinging, Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline,Superficial Observation:Hyperpigmentation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline,Superficial Observation: Scaling-Flacking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Superficial Observation: Glazing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, Erythema: Trace Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, Erythema: Moderate Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, Letter Grade: Burning, Stinging, Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, Superficial Observation: Peeling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, Superficial Observation: Scaling-Flacking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Erythema: Trace Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Letter Grade: Burning, Stinging, Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Superficial Observation: Scaling-Flacking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3, Erythema: Trace Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3, Letter Grade: Burning, Stinging, Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Superficial Observation: Hyperpigmentation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic and Diastolic Blood Pressure at Week 1, 2, 3, 4</title>
        <description>Blood pressure (BP) was measured in duplicate (approximately 5 minutes apart) using a standard calibrated BP measuring device. BP defined as pressure exerted by circulating blood upon walls of blood vessels. Diastolic BP is minimum pressure in arteries, near beginning of cardiac cycle when ventricles are filled with blood. Systolic BP is peak pressure in arteries, near end of the cardiac cycle when ventricles are contracting. Normal blood pressure is less than 120 millimeters of mercury (mmHg) systolic and less than 80 mmHg diastolic. Change=value at week 1, 2, 3, 4 minus value at baseline.</description>
        <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
        <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Number Analyzed=number of participants evaluable for this measure at specified time points for each treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic and Diastolic Blood Pressure at Week 1, 2, 3, 4</title>
          <description>Blood pressure (BP) was measured in duplicate (approximately 5 minutes apart) using a standard calibrated BP measuring device. BP defined as pressure exerted by circulating blood upon walls of blood vessels. Diastolic BP is minimum pressure in arteries, near beginning of cardiac cycle when ventricles are filled with blood. Systolic BP is peak pressure in arteries, near end of the cardiac cycle when ventricles are contracting. Normal blood pressure is less than 120 millimeters of mercury (mmHg) systolic and less than 80 mmHg diastolic. Change=value at week 1, 2, 3, 4 minus value at baseline.</description>
          <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Number Analyzed=number of participants evaluable for this measure at specified time points for each treatment groups.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Diastolic BP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.91" spread="9.87"/>
                    <measurement group_id="O2" value="74.81" spread="9.67"/>
                    <measurement group_id="O3" value="75.52" spread="8.63"/>
                    <measurement group_id="O4" value="76.60" spread="10.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 1: Diastolic BP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" spread="7.24"/>
                    <measurement group_id="O2" value="-2.04" spread="7.17"/>
                    <measurement group_id="O3" value="-2.54" spread="8.32"/>
                    <measurement group_id="O4" value="-1.94" spread="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: Diastolic BP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="7.41"/>
                    <measurement group_id="O2" value="-2.25" spread="5.89"/>
                    <measurement group_id="O3" value="-3.63" spread="9.50"/>
                    <measurement group_id="O4" value="0.29" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 3: Diastolic BP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="8.09"/>
                    <measurement group_id="O2" value="-3.81" spread="9.04"/>
                    <measurement group_id="O3" value="-0.26" spread="8.64"/>
                    <measurement group_id="O4" value="-2.13" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: Diastolic BP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="7.97"/>
                    <measurement group_id="O2" value="-1.31" spread="6.94"/>
                    <measurement group_id="O3" value="-2.61" spread="7.28"/>
                    <measurement group_id="O4" value="-1.06" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Systolic BP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.57" spread="14.83"/>
                    <measurement group_id="O2" value="115.42" spread="12.77"/>
                    <measurement group_id="O3" value="125.62" spread="16.26"/>
                    <measurement group_id="O4" value="116.05" spread="15.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 1: Systolic BP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="8.48"/>
                    <measurement group_id="O2" value="3.58" spread="8.76"/>
                    <measurement group_id="O3" value="-2.85" spread="8.20"/>
                    <measurement group_id="O4" value="3.39" spread="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: Systolic BP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="12.99"/>
                    <measurement group_id="O2" value="0.33" spread="7.24"/>
                    <measurement group_id="O3" value="-3.67" spread="8.96"/>
                    <measurement group_id="O4" value="-3.07" spread="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 3: Systolic BP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="12.14"/>
                    <measurement group_id="O2" value="0.65" spread="9.29"/>
                    <measurement group_id="O3" value="0.67" spread="8.62"/>
                    <measurement group_id="O4" value="-0.81" spread="11.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: Systolic BP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="10.42"/>
                    <measurement group_id="O2" value="2.96" spread="9.73"/>
                    <measurement group_id="O3" value="-5.07" spread="9.04"/>
                    <measurement group_id="O4" value="1.06" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate at Week 1, 2, 3, 4</title>
        <description>Heart (pulse) rate was measured in duplicate (approximately 5 minutes apart) for a minimum of 30 seconds. Heart rate is the number of heartbeats per unit of time, usually per minute. The heart rate is based on the number of contractions of the ventricles (the lower chambers of the heart). Change=value at week 1, 2, 3, 4 minus value at baseline.</description>
        <time_frame>Baseline, Week 1, 2, 3, 4</time_frame>
        <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Number Analyzed=participants evaluable for this measure at specified time points for each treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate at Week 1, 2, 3, 4</title>
          <description>Heart (pulse) rate was measured in duplicate (approximately 5 minutes apart) for a minimum of 30 seconds. Heart rate is the number of heartbeats per unit of time, usually per minute. The heart rate is based on the number of contractions of the ventricles (the lower chambers of the heart). Change=value at week 1, 2, 3, 4 minus value at baseline.</description>
          <population>FAS included all participants who were randomized to study and received at least 1 dose of investigational drug (CP-690,550 or vehicle). Number Analyzed=participants evaluable for this measure at specified time points for each treatment groups.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.24" spread="10.64"/>
                    <measurement group_id="O2" value="66.77" spread="6.24"/>
                    <measurement group_id="O3" value="66.12" spread="6.82"/>
                    <measurement group_id="O4" value="73.75" spread="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="9.29"/>
                    <measurement group_id="O2" value="3.12" spread="9.98"/>
                    <measurement group_id="O3" value="2.28" spread="8.31"/>
                    <measurement group_id="O4" value="6.39" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.95" spread="10.75"/>
                    <measurement group_id="O2" value="2.71" spread="6.18"/>
                    <measurement group_id="O3" value="2.04" spread="7.91"/>
                    <measurement group_id="O4" value="0.36" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="7.96"/>
                    <measurement group_id="O2" value="2.27" spread="8.76"/>
                    <measurement group_id="O3" value="4.45" spread="12.41"/>
                    <measurement group_id="O4" value="2.50" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="7.73"/>
                    <measurement group_id="O2" value="2.85" spread="10.60"/>
                    <measurement group_id="O3" value="0.63" spread="7.08"/>
                    <measurement group_id="O4" value="-2.00" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Electrocardiogram (ECG) Findings at Week 4</title>
        <description>A single standard supine 12-lead Electrocardiogram (ECG) was performed after the participant had rested quietly for at least 10 minutes. ECG parameters included RR interval, PR interval, QRS complex, QT interval, QTcB (corrected for heart rate using Bazett's formula) interval, and QTcF (corrected for heart rate using Fridericia's formula) interval.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>Safety analysis set included all participants who received at least one dose of the investigational drug (CP-690,550 or vehicle). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Electrocardiogram (ECG) Findings at Week 4</title>
          <description>A single standard supine 12-lead Electrocardiogram (ECG) was performed after the participant had rested quietly for at least 10 minutes. ECG parameters included RR interval, PR interval, QRS complex, QT interval, QTcB (corrected for heart rate using Bazett's formula) interval, and QTcF (corrected for heart rate using Fridericia's formula) interval.</description>
          <population>Safety analysis set included all participants who received at least one dose of the investigational drug (CP-690,550 or vehicle). Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this measure.</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: RR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="984.7" spread="165.17"/>
                    <measurement group_id="O2" value="958.4" spread="120.78"/>
                    <measurement group_id="O3" value="962.3" spread="111.02"/>
                    <measurement group_id="O4" value="887.9" spread="124.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: RR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.7" spread="80.50"/>
                    <measurement group_id="O2" value="-21.5" spread="114.31"/>
                    <measurement group_id="O3" value="-23.1" spread="107.99"/>
                    <measurement group_id="O4" value="-8.8" spread="78.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.3" spread="19.80"/>
                    <measurement group_id="O2" value="163.8" spread="26.10"/>
                    <measurement group_id="O3" value="159.0" spread="22.27"/>
                    <measurement group_id="O4" value="170.4" spread="20.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: PR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="11.89"/>
                    <measurement group_id="O2" value="2.0" spread="10.41"/>
                    <measurement group_id="O3" value="1.7" spread="16.73"/>
                    <measurement group_id="O4" value="4.2" spread="11.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: QRS Complex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" spread="5.94"/>
                    <measurement group_id="O2" value="93.8" spread="9.78"/>
                    <measurement group_id="O3" value="95.3" spread="8.38"/>
                    <measurement group_id="O4" value="93.0" spread="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: QRS Complex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="7.33"/>
                    <measurement group_id="O2" value="-2.8" spread="9.11"/>
                    <measurement group_id="O3" value="-1.3" spread="7.11"/>
                    <measurement group_id="O4" value="-0.3" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: QT Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400.2" spread="21.45"/>
                    <measurement group_id="O2" value="400.1" spread="26.91"/>
                    <measurement group_id="O3" value="411.1" spread="26.46"/>
                    <measurement group_id="O4" value="392.3" spread="19.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: QT Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="11.40"/>
                    <measurement group_id="O2" value="-1.2" spread="22.42"/>
                    <measurement group_id="O3" value="-8.1" spread="27.36"/>
                    <measurement group_id="O4" value="2.9" spread="16.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: QTcB Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406.3" spread="24.59"/>
                    <measurement group_id="O2" value="409.8" spread="18.53"/>
                    <measurement group_id="O3" value="420.1" spread="19.96"/>
                    <measurement group_id="O4" value="418.6" spread="26.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: QTcB Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="16.83"/>
                    <measurement group_id="O2" value="5.8" spread="15.03"/>
                    <measurement group_id="O3" value="-2.9" spread="19.77"/>
                    <measurement group_id="O4" value="5.4" spread="16.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: QTcF Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404.0" spread="17.23"/>
                    <measurement group_id="O2" value="406.5" spread="18.16"/>
                    <measurement group_id="O3" value="417.0" spread="19.39"/>
                    <measurement group_id="O4" value="409.6" spread="20.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: QTcF Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="12.88"/>
                    <measurement group_id="O2" value="3.0" spread="12.86"/>
                    <measurement group_id="O3" value="-4.8" spread="19.62"/>
                    <measurement group_id="O4" value="4.3" spread="14.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin Level at Week 2, 4</title>
        <time_frame>Baseline, Week 2, 4</time_frame>
        <population>FAS population included all participants who were randomized to the study and received at least one dose of the randomized investigational drug (CP-690,550 or vehicle). Number Analyzed =participants evaluable for this measure at specified time points for each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin Level at Week 2, 4</title>
          <population>FAS population included all participants who were randomized to the study and received at least one dose of the randomized investigational drug (CP-690,550 or vehicle). Number Analyzed =participants evaluable for this measure at specified time points for each treatment group.</population>
          <units>grams per deciliter (g/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.56" spread="1.34"/>
                    <measurement group_id="O2" value="13.68" spread="1.41"/>
                    <measurement group_id="O3" value="14.21" spread="1.26"/>
                    <measurement group_id="O4" value="13.90" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.59"/>
                    <measurement group_id="O2" value="0.12" spread="0.48"/>
                    <measurement group_id="O3" value="0.19" spread="0.52"/>
                    <measurement group_id="O4" value="-0.06" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.56"/>
                    <measurement group_id="O2" value="-0.08" spread="0.66"/>
                    <measurement group_id="O3" value="-0.02" spread="0.49"/>
                    <measurement group_id="O4" value="-0.09" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelet and Neutrophil Count at Week 2, 4</title>
        <time_frame>Baseline, Week 2, 4</time_frame>
        <population>FAS population included all participants who were randomized to the study and received at least one dose of the randomized investigational drug (CP-690,550 or vehicle). Number Analyzed =participants evaluable for this measure at specified time points for each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelet and Neutrophil Count at Week 2, 4</title>
          <population>FAS population included all participants who were randomized to the study and received at least one dose of the randomized investigational drug (CP-690,550 or vehicle). Number Analyzed =participants evaluable for this measure at specified time points for each treatment group.</population>
          <units>10^3 per cubic millimeter (10^3/mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Platelet</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227.30" spread="69.97"/>
                    <measurement group_id="O2" value="212.85" spread="58.76"/>
                    <measurement group_id="O3" value="233.68" spread="50.79"/>
                    <measurement group_id="O4" value="214.90" spread="58.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: Platelet</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38" spread="20.88"/>
                    <measurement group_id="O2" value="6.85" spread="28.31"/>
                    <measurement group_id="O3" value="0.00" spread="21.37"/>
                    <measurement group_id="O4" value="13.00" spread="15.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: Platelet</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="13.88"/>
                    <measurement group_id="O2" value="-2.46" spread="15.33"/>
                    <measurement group_id="O3" value="-7.30" spread="23.07"/>
                    <measurement group_id="O4" value="2.50" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Neutrophil</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="1.36"/>
                    <measurement group_id="O2" value="3.75" spread="1.06"/>
                    <measurement group_id="O3" value="4.71" spread="1.04"/>
                    <measurement group_id="O4" value="3.79" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: Neutrophil</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.59"/>
                    <measurement group_id="O2" value="0.00" spread="0.57"/>
                    <measurement group_id="O3" value="0.06" spread="0.88"/>
                    <measurement group_id="O4" value="0.23" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: Neutrophil</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.77"/>
                    <measurement group_id="O2" value="-0.21" spread="0.41"/>
                    <measurement group_id="O3" value="-0.34" spread="0.94"/>
                    <measurement group_id="O4" value="0.01" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Creatinine Level at Week 2, 4</title>
        <time_frame>Baseline, Week 2, 4</time_frame>
        <population>FAS population included all participants who were randomized to the study and received at least one dose of the randomized investigational drug (CP-690,550 or vehicle). Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Creatinine Level at Week 2, 4</title>
          <population>FAS population included all participants who were randomized to the study and received at least one dose of the randomized investigational drug (CP-690,550 or vehicle). Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
          <units>milligram per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.22"/>
                    <measurement group_id="O2" value="0.89" spread="0.19"/>
                    <measurement group_id="O3" value="0.93" spread="0.14"/>
                    <measurement group_id="O4" value="0.89" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.06"/>
                    <measurement group_id="O2" value="-0.01" spread="0.06"/>
                    <measurement group_id="O3" value="0.03" spread="0.07"/>
                    <measurement group_id="O4" value="-0.04" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.06"/>
                    <measurement group_id="O2" value="-0.01" spread="0.07"/>
                    <measurement group_id="O3" value="-0.02" spread="0.07"/>
                    <measurement group_id="O4" value="-0.00" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Creatine Kinase (CK) Level at Week 2, 4</title>
        <time_frame>Baseline, Week 2, 4</time_frame>
        <population>FAS population included all participants who were randomized to the study and received at least one dose of the randomized investigational drug (CP-690,550 or vehicle). Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 1</title>
            <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 2</title>
            <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Creatine Kinase (CK) Level at Week 2, 4</title>
          <population>FAS population included all participants who were randomized to the study and received at least one dose of the randomized investigational drug (CP-690,550 or vehicle). Number Analyzed=participants evaluable for this measure at specified time points for each treatment group.</population>
          <units>international unit per liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: AST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.57" spread="12.35"/>
                    <measurement group_id="O2" value="22.77" spread="6.69"/>
                    <measurement group_id="O3" value="23.04" spread="14.04"/>
                    <measurement group_id="O4" value="21.10" spread="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: AST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="7.46"/>
                    <measurement group_id="O2" value="-1.23" spread="3.83"/>
                    <measurement group_id="O3" value="1.84" spread="4.59"/>
                    <measurement group_id="O4" value="-2.00" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: AST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="7.18"/>
                    <measurement group_id="O2" value="-1.08" spread="3.09"/>
                    <measurement group_id="O3" value="0.70" spread="5.98"/>
                    <measurement group_id="O4" value="0.63" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: ALT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.22" spread="26.77"/>
                    <measurement group_id="O2" value="28.08" spread="16.01"/>
                    <measurement group_id="O3" value="24.28" spread="17.81"/>
                    <measurement group_id="O4" value="27.60" spread="13.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: ALT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.48" spread="14.88"/>
                    <measurement group_id="O2" value="-3.54" spread="4.77"/>
                    <measurement group_id="O3" value="2.12" spread="4.75"/>
                    <measurement group_id="O4" value="-0.67" spread="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: ALT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.76" spread="17.67"/>
                    <measurement group_id="O2" value="-3.23" spread="5.45"/>
                    <measurement group_id="O3" value="0.61" spread="5.75"/>
                    <measurement group_id="O4" value="-0.13" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: CK</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.91" spread="67.38"/>
                    <measurement group_id="O2" value="106.62" spread="73.11"/>
                    <measurement group_id="O3" value="100.16" spread="61.20"/>
                    <measurement group_id="O4" value="93.10" spread="32.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: CK</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="40.05"/>
                    <measurement group_id="O2" value="-11.00" spread="17.88"/>
                    <measurement group_id="O3" value="13.00" spread="47.55"/>
                    <measurement group_id="O4" value="8.00" spread="56.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: CK</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" spread="49.49"/>
                    <measurement group_id="O2" value="19.62" spread="73.16"/>
                    <measurement group_id="O3" value="-2.13" spread="25.91"/>
                    <measurement group_id="O4" value="-6.88" spread="22.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of CP-690,550</title>
        <description>Summary statistics were calculated by setting concentration values below the lower limit of quantification (lower limit of quantification=0.1 nanogram per milliliter [ng/mL]) to zero. Summary statistics were not presented if number of observations above lower limit of quantification (NALQ) = 0.</description>
        <time_frame>0 (predose), 1, 2 and 4-9 hours postdose on Day 29 or early termination</time_frame>
        <population>Pharmacokinetic analysis set included all treated participants who had at least one plasma concentration value above the lower limit of quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CP-690,550 Ointment 1</title>
            <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>2% CP-690,550 Ointment 2</title>
            <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of CP-690,550</title>
          <description>Summary statistics were calculated by setting concentration values below the lower limit of quantification (lower limit of quantification=0.1 nanogram per milliliter [ng/mL]) to zero. Summary statistics were not presented if number of observations above lower limit of quantification (NALQ) = 0.</description>
          <population>Pharmacokinetic analysis set included all treated participants who had at least one plasma concentration value above the lower limit of quantification.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1336" spread="0.1499"/>
                    <measurement group_id="O2" value="0.0313" spread="0.0742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1522" spread="0.1839"/>
                    <measurement group_id="O2" value="0.0434" spread="0.1083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1548" spread="0.2089"/>
                    <measurement group_id="O2" value="0.0570" spread="0.1459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1514" spread="0.2244"/>
                    <measurement group_id="O2" value="0.0553" spread="0.1420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>2% CP-690,550 Ointment 1</title>
          <description>CP-690,550 2% ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Vehicle 1</title>
          <description>Placebo ointment (Vehicle 1), matched to 2% CP-690,550 ointment 1, containing a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
        </group>
        <group group_id="E3">
          <title>2% CP-690,550 Ointment 2</title>
          <description>CP-690,550 2% ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Vehicle 2</title>
          <description>Placebo ointment (Vehicle 2), matched to 2% CP-690,550 ointment 2, without a dermal penetration agent, was applied topically to a 300 cm^2 treatment area twice daily at an application coverage of 3 mg/cm^2 for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Eye infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary tract infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penis disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

